Fabrizio Stocchi


Country: Italy


  1. request reprint
    Stocchi F. Optimising levodopa therapy for the management of Parkinson's disease. J Neurol. 2005;252 Suppl 4:IV43-IV48 pubmed
    ..It can, therefore, be suggested that the onset of dyskinesia may be prolonged if levodopa is administered in a more continuous manner by administering it as a combination of levodopa/DDCI and COMT inhibitor. ..
  2. Stocchi F, Tagliati M, Olanow C. Treatment of levodopa-induced motor complications. Mov Disord. 2008;23 Suppl 3:S599-612 pubmed publisher
    ..Key Words: Advanced PD, dyskinesias, motor fluctuations, levodopa, dopamine agonists, COMT inhibitors, MAO-B inhibitors. ..
  3. Stocchi F. Dopamine receptor agonists in the treatment of advanced Parkinson's disease. Parkinsonism Relat Disord. 2009;15 Suppl 4:S54-7 pubmed publisher
    ..Dopamine receptor agonists have been extensively used as add-on therapy to L-dopa to treat motor complications. In this article we review the role of dopamine receptor agonists in the treatment of advanced parkinsonian patients. ..
  4. Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, et al. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014;20:1335-40 pubmed publisher
    ..In advanced PD, IPX066 showed improved efficacy, compared with CL + E, and appeared to be well tolerated. ..
  5. Stocchi F, Radicati F, Torti M. Drug safety evaluation of ropinirole prolonged release. Expert Opin Drug Saf. 2014;13:383-9 pubmed publisher
    ..RPR was generally well tolerated in both early and advanced Parkinsonian patients. ..
  6. Stocchi F. Continuous dopaminergic stimulation and novel formulations of dopamine agonists. J Neurol. 2011;258:S316-22 pubmed publisher
    ..In this paper the role of new formulations of dopamine agonists in the treatment of parkinsonian patients at different stages of the disease is reviewed. ..
  7. Stocchi F, Rascol O, Hauser R, Huyck S, Tzontcheva A, Capece R, et al. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. Neurology. 2017;88:2198-2206 pubmed publisher
    ..Clinicaltrials.gov: NCT01155479. This study provides Class I evidence that for patients with early PD, preladenant is not effective as monotherapy at the doses studied (2, 5, 10 mg). ..
  8. Stocchi F, Zappia M, Dall Armi V, Kulisevsky J, Lamberti P, Obeso J. Melevodopa/carbidopa effervescent formulation in the treatment of motor fluctuations in advanced Parkinson's disease. Mov Disord. 2010;25:1881-7 pubmed publisher
    ..3%); L/C: 1 patient (1.4%)]. This study failed to meet the primary endpoint (P = 0.07); however, there was a trend in favour of the M/C preparation, which deserves further attention...
  9. Stocchi F, Giorgi L, Hunter B, Schapira A. PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease. Mov Disord. 2011;26:1259-65 pubmed publisher
    ..Despite dosing differences, the PR titration regimen was generally well tolerated, with an AE profile similar to that of IR. ..

More Information


  1. Stocchi F, Torti M. Constipation in Parkinson's Disease. Int Rev Neurobiol. 2017;134:811-826 pubmed publisher
    ..An accurate diagnosis and an adequate treatment of constipation it is pivotal to prevent complications such as intestinal occlusion and to ensure an optimal clinical response to levodopa. ..